Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 2/20 | 0.61 |
| ▸ | ADH1C | P00326 | 2/20 | 0.61 |
| ▸ | ADH1A | P07327 | 2/20 | 0.61 |
| ▸ | ADH7 | P40394 | 2/20 | 0.61 |
| ▸ | ADH4 | P08319 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15213162 | 0.87 | — | — | |
| SCHEMBL207500 | 0.83 | — | — | |
| SCHEMBL1608989 | 0.80 | — | — | |
| SCHEMBL17732249 | 0.78 | KDM1A (0.38) | ADH1BADH1CADH1AADH7ADH4 | |
| SCHEMBL304641 | 0.78 | — | — | |
| SCHEMBL5360130 | 0.78 | KCNH3 (0.37) | ADH1BADH1CADH1AADH7ADH4 | |
| SCHEMBL21746653 | 0.77 | ADH1B (0.35) | ADH1BADH1CADH1AADH7ADH4 | |
| SCHEMBL15213163 | 0.76 | — | — | |
| SCHEMBL8952019 | 0.76 | ADH1A (1.00) | ADH1BADH1CADH1AADH7ADH4 | |
| SCHEMBL303776 | 0.76 | ADH1A (1.00) | ADH1BADH1CADH1AADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | claimed |
| EP-2450374-A1 | PEPTIDE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | claimed |
| US-20190209539-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-11 | — | — | US | disclosed |
| EP-3500259-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica NV (BE) | 2019-06-26 | — | — | EP | disclosed |
| EP-3481394-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018037342-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-01 | — | — | WO | disclosed |
| US-20180008587-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | Jaressen Pharmaceutica NV (BE) | 2018-01-11 | — | — | US | disclosed |
| WO-2018009694-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-11 | — | — | WO | disclosed |
| US-9670166-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-06 | — | — | US | disclosed |
| EP-2450374-B9 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| WO-2016044585-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-2450374-A1 | PEPTIDE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20100137303-A1 | NEW COMPOUND 255 | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137303-A1 | NEW COMPOUND 255 | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2009147431-A1 | THIAZOLO [5, 4-B] PYRIDINE AND OXAZOLO [5, 4-B] PYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | WO | disclosed |
| US-20080312207-A1 | Compounds | SYNGENTA CROP PROTECTION AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1718625-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080360-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312207-A1 | Compounds | GRK4, PTGER4, GRK5 | ADH1B 2010/4885ADH1C 1299/4885ADH1A 1539/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ADH1B 3729/4885ADH1C 2210/4885ADH1A 2662/4885 |
| US-20100137303-A1 | NEW COMPOUND 255 | MRPS35, MRPL21, CYP51A1 | ADH1B 3326/4885ADH1C 4391/4885ADH1A 2575/4885 |
| US-20190209539-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | AR, SHBG, NR5A1 | ADH1B 378/4885ADH1C 476/4885ADH1A 208/4885 |
| US-20180008587-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | AR, SHBG, NR5A1 | ADH1B 378/4885ADH1C 476/4885ADH1A 208/4885 |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | GLP1R, GIPR, SCTR | ADH1B 3798/4885ADH1C 2765/4885ADH1A 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.